Akihiro Nakamura

Akihiro Nakamura

Auto-generated profile, based on publicly available information

Akihiro Nakamura

Department of Medicine, Division of Rheumatology, Queen’s University, Kingston, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
ANAkihiro Nakamura
Akihiro Nakamura
YRY. Raja Rampersaud
Y. Raja Rampersaud
ASAnirudh Sharma
Anirudh Sharma
SLStephen J. Lewis
Stephen J. Lewis
BWBrian Wu
Brian Wu
MKMohit Kapoor
Mohit Kapoor
Osteoarthritis (OA) of spine (facet joints [FJs]) is one of the major causes of severe low back pain and disability worldwide. The degeneration of facet cartilage is a hallmark of FJ OA. However, endogenous mechanisms that initiate degeneration of facet cartilage are unknown, and there are no disease-modifying therapies to stop FJ OA. In this study, we have identified microRNAs (small noncoding RNAs) as mediators of FJ cartilage degeneration. We first established a cohort of patients with varying degrees of facet cartilage degeneration (control group: normal or mild facet cartilage degeneration; FJ OA group: moderate to severe facet cartilage degeneration) and then screened 2,100 miRNAs and identified 2 miRNAs (miR-181a-5p and miR-4454) that were significantly elevated in FJ OA cartilage compared with control facet cartilage. We further explored their role, function, and signaling mechanisms using computational, in vitro functional, and in vivo studies. We specifically indicate that miR-181a-5p and miR-4454 are involved in promoting inflammatory, catabolic, and cell death activity in FJ chondrocytes. This is the first report to our knowledge that identifies miR-181a-5p and miR-4454 as mediators of cartilage degeneration in FJs and potential therapeutic targets for stopping cartilage degeneration.

20 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
ANAkihiro Nakamura
Akihiro Nakamura
FZFanxing Zeng
Fanxing Zeng
SNSayaka Nakamura
Sayaka Nakamura
KRKyle T. Reid
Kyle T. Reid
EGEric Gracey
Eric Gracey
NHNigil Haroon
Nigil Haroon
Macrophage migration inhibitory factor produced by neutrophils worsens spondyloarthritis by inducing a pathogenic T H 17 phenotype in T regs .

24 May 2024 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
RORyunosuke Ohno
Ryunosuke Ohno
ANAkihiro Nakamura
Akihiro Nakamura
Despite advancements in managing autoimmune rheumatic diseases (ARDs) with existing treatments, many patients still encounter challenges such as inadequate responses, difficulty in maintaining remission, and side effects. Chimeric Antigen Receptor (CAR) T-cell therapy, originally developed for cancer, has now emerged as a promising option for cases of refractory ARDs. A search of the literature was conducted to compose a narrative review exploring the current evidence, potential safety, limitations, potential modifications, and future directions of CAR-T cells in ARDs. CAR-T cell therapy has been administered to patients with refractory ARDs, including systemic lupus erythematosus, antisynthetase syndrome, and systemic sclerosis, demonstrating significant improvement. Notable responses include enhanced clinical symptoms, reduced serum autoantibody titers, and sustained remissions in disease activity. Preclinical and in vitro studies using both animal and human samples also support the efficacy and elaborate on potential mechanisms of CAR-T cells against antineutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis. While cautious monitoring of adverse events, such as cytokine release syndrome, is crucial, the therapy appears to be highly tolerable. Nevertheless, challenges persist, including cost, durability due to potential CAR-T cell exhaustion, and manufacturing complexities, urging the development of innovative solutions to further enhance CAR-T cell therapy accessibility in ARDs. CAR-T cell therapy for refractory ARDs has demonstrated high effectiveness. While no significant warning signs are currently reported, achieving a balance between therapeutic efficacy and safety is vital in adapting CAR-T cell therapy for ARDs. Moreover, there is significant potential for technological advancements to enhance the delivery of this treatment to patients, thereby ensuring safer and more effective disease control for patients.

5 June 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
ANAkihiro Nakamura
Akihiro Nakamura
SJSungsin Jo
Sungsin Jo
SNSayaka Nakamura
Sayaka Nakamura
MAMansi K. Aparnathi
Mansi K. Aparnathi
SBShaghayegh Foroozan Boroojeni
Shaghayegh Foroozan Boroojeni
NHNigil Haroon
Nigil Haroon

2 September 2021 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
MKMasaki Kusuda
Masaki Kusuda
NHNigil Haroon
Nigil Haroon
ANAkihiro Nakamura
Akihiro Nakamura
Despite increasing availability of treatments for spondyloarthritis (SpA) including tumour necrosis factor (TNF) and interleukin-17 (IL-17) inhibitors, there is no established treatment that abates new bone formation (NBF) in ankylosing spondylitis (AS), a subset of SpA. Recent research on TNF has revealed the increased level of transmembrane TNF in the joint tissue of SpA patients compared to that of rheumatoid arthritis patients, which appears to facilitate TNF-driven osteo-proliferative changes in AS. In addition, there is considerable interest in the central role of IL-23/IL-17 axis in type 3 immunity and the therapeutic potential of blocking this axis to ameliorate enthesitis and NBF in AS. AS immunopathology involves a variety of immune cells, including both innate and adoptive immune cells, to orchestrate the immune response driving type 3 immunity. In response to external stimuli of inflammatory cytokines, local osteo-chondral progenitor cells activate intra-cellular anabolic molecules and signals involving hedgehog, bone morphogenetic proteins, receptor activator of nuclear factor kappa-B ligand, and Wnt pathways to promote NBF in AS. Here, we provide an overview of the current immunopathology and future directions for the treatment of enthesitis and NBF associated with AS.

2 February 2021 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
ANAkihiro Nakamura
Akihiro Nakamura
SBShaghayegh Foroozan Boroojeni
Shaghayegh Foroozan Boroojeni
NHNigil Haroon
Nigil Haroon